Evidence map›Paper›PMID 41127338›Full record

ArticleCancer drug resistance (Alhambra, Calif.)2025

Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors.

Cristina Corno, Debora Russo, Francesco Pignotti, Francesca De Giorgi, Ilaria Penna, Francesco Saccoliti, Matteo Costantino, Luca Mirra, Pietro Pettinari, Nives Carenini and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer drug resistance (Alhambra, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Cristina CornoUnit of Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Debora RussoD3-PharmaChemistry, Istituto Italiano di Tecnologia, Genoa 16163, Italy.
Francesco PignottiDepartment of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy.
Francesca De GiorgiD3-PharmaChemistry, Istituto Italiano di Tecnologia, Genoa 16163, Italy.
Ilaria PennaD3-PharmaChemistry, Istituto Italiano di Tecnologia, Genoa 16163, Italy.
Francesco SaccolitiD3-PharmaChemistry, Istituto Italiano di Tecnologia, Genoa 16163, Italy.
Matteo CostantinoUnit of Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Luca MirraUnit of Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Pietro PettinariUnit of Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Nives CareniniUnit of Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Elisabetta CornaUnit of Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Nunzio PertaDepartment of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy.
Chiara M CiniselliUnit of Bioinformatics and Biostatistics, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Pietro PratesiUnit of Bioinformatics and Biostatistics, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Rita ScarpelliMedicinal Chemistry and Technologies for Drug Discovery and Delivery Facility, Istituto Italiano di Tecnologia, Genoa 16163, Italy.
Fabio BertozziD3-PharmaChemistry, Istituto Italiano di Tecnologia, Genoa 16163, Italy.
Paolo VerderioUnit of Bioinformatics and Biostatistics, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Giovanni L BerettaUnit of Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
Giovanni Di MuccioDepartment of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy.
Daniele Di MarinoDepartment of Life and Environmental Sciences, Polytechnic University of Marche, Ancona 60131, Italy.
Tiziano BandieraD3-PharmaChemistry, Istituto Italiano di Tecnologia, Genoa 16163, Italy.
Paola PeregoUnit of Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cisplatinDeubiquitinasesdrug resistanceproteasome

Identifiers

PMID41127338
PMCPMC12539213

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.